• Recruiting

NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM

Updated: Sep 24

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

UCSD Health - University of Clifornia San Diego - Moores Cancer Center myeoma

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.


Sponsor

University of California, San Diego


Collaborators

Celgene

Takeda

Janssen, LP

 

ClinicalTrials.gov Identifier: NCT03590652

Official Title: Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)

First Posted : July 18, 2018

Click here for details on ClinicalTrials.gov

 

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Ixazomib: National Cancer Institute

Ixazomib: MedlinePlus Drug Information


Pomalidomide: National Cancer Institute

Pomalidomide: MedlinePlus Drug Information

 

Locations

United States, California

UCSD Health - University of Clifornia San Diego - Moores Cancer Center

https://clinicaltrials.ucsd.edu/multiple-myeloma

https://health.ucsd.edu/Pages/default.aspx











Posts Archive